ZA200707929B - Azole derivatives in the form of lipase and phospholipase inhibitors - Google Patents

Azole derivatives in the form of lipase and phospholipase inhibitors

Info

Publication number
ZA200707929B
ZA200707929B ZA200707929A ZA200707929A ZA200707929B ZA 200707929 B ZA200707929 B ZA 200707929B ZA 200707929 A ZA200707929 A ZA 200707929A ZA 200707929 A ZA200707929 A ZA 200707929A ZA 200707929 B ZA200707929 B ZA 200707929B
Authority
ZA
South Africa
Prior art keywords
lipase
azole derivatives
phospholipase inhibitors
phospholipase
inhibitors
Prior art date
Application number
ZA200707929A
Other languages
English (en)
Inventor
Zoller Gerhard
Petry Stefan
Mueller Guenter
Heuer Hubert
Tennagels Norbert
Original Assignee
Sanofi Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36694158&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ZA200707929(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sanofi Aventis filed Critical Sanofi Aventis
Publication of ZA200707929B publication Critical patent/ZA200707929B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/20—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/423—Oxazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D275/00—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings
    • C07D275/04—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
ZA200707929A 2005-04-20 2007-09-17 Azole derivatives in the form of lipase and phospholipase inhibitors ZA200707929B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE102005018389A DE102005018389A1 (de) 2005-04-20 2005-04-20 Azolderivate als Inhibitoren von Lipasen und Phospholipasen

Publications (1)

Publication Number Publication Date
ZA200707929B true ZA200707929B (en) 2008-12-31

Family

ID=36694158

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200707929A ZA200707929B (en) 2005-04-20 2007-09-17 Azole derivatives in the form of lipase and phospholipase inhibitors

Country Status (20)

Country Link
US (1) US8921404B2 (fr)
EP (1) EP1874741A1 (fr)
JP (1) JP2008536884A (fr)
KR (1) KR20080004501A (fr)
CN (1) CN101160293A (fr)
AR (1) AR053228A1 (fr)
AU (1) AU2006237127A1 (fr)
BR (1) BRPI0608495A2 (fr)
CA (1) CA2606301A1 (fr)
DE (1) DE102005018389A1 (fr)
IL (1) IL186635A0 (fr)
MA (1) MA29393B1 (fr)
MX (1) MX2007012732A (fr)
MY (1) MY142441A (fr)
NO (1) NO20075938L (fr)
NZ (1) NZ562694A (fr)
RU (1) RU2414458C2 (fr)
TW (1) TW200722421A (fr)
WO (1) WO2006111321A1 (fr)
ZA (1) ZA200707929B (fr)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2007283113A1 (en) 2006-08-08 2008-02-14 Sanofi-Aventis Arylaminoaryl-alkyl-substituted imidazolidine-2,4-diones, processes for preparing them, medicaments comprising these compounds, and their use
CA2682891A1 (fr) 2007-04-05 2008-10-16 Sanofi-Aventis 5-oxo-isoxazoles utilises comme inhibiteurs de lipases et de phospholipases
CN101646655A (zh) 2007-04-05 2010-02-10 塞诺菲-安万特股份有限公司 作为脂肪酶和磷脂酶抑制剂的咪唑烷甲酰胺衍生物
EP2025674A1 (fr) 2007-08-15 2009-02-18 sanofi-aventis Tetrahydronaphthaline substituée, son procédé de fabrication et son utilisation en tant que médicament
UY31968A (es) 2008-07-09 2010-01-29 Sanofi Aventis Nuevos derivados heterocíclicos, sus procesos para su preparación, y sus usos terapéuticos
WO2010044441A1 (fr) 2008-10-17 2010-04-22 塩野義製薬株式会社 Dérivé amide d'acide acétique ayant une activité inhibitrice d'une lipase endothéliale vasculaire
WO2010068601A1 (fr) 2008-12-08 2010-06-17 Sanofi-Aventis Hydrate de fluoroglycoside hétéroaromatique cristallin, ses procédés de fabrication, ses procédés d'utilisation et compositions pharmaceutiques le contenant
GB2466121B (en) * 2008-12-15 2010-12-08 Amira Pharmaceuticals Inc Antagonists of lysophosphatidic acid receptors
CA2771278A1 (fr) 2009-08-26 2011-03-03 Sanofi Nouveaux hydrates de fluoroglycoside heteroaromatiques cristallins, substances pharmaceutiques comprenant ces composes et leur utilisation
KR20120123325A (ko) 2009-12-15 2012-11-08 시오노기세야쿠 가부시키가이샤 혈관 내피 리파아제 저해 활성을 갖는 옥사디아졸 유도체
WO2011107494A1 (fr) 2010-03-03 2011-09-09 Sanofi Nouveaux dérivés aromatiques de glycoside, médicaments contenants ces composés, et leur utilisation
EP2582709B1 (fr) 2010-06-18 2018-01-24 Sanofi Dérivés d'azolopyridin-3-one en tant qu'inhibiteurs de lipases et de phospholipases
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
KR101898610B1 (ko) 2010-08-31 2018-09-14 서울대학교산학협력단 ＰＰＡＲδ 활성물질의 태자 재프로그래밍 용도
US8871758B2 (en) 2011-03-08 2014-10-28 Sanofi Tetrasubstituted oxathiazine derivatives, method for producing them, their use as medicine and drug containing said derivatives and the use thereof
US8828994B2 (en) 2011-03-08 2014-09-09 Sanofi Di- and tri-substituted oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
WO2012120052A1 (fr) 2011-03-08 2012-09-13 Sanofi Dérivés d'oxathiazine substitués par des carbocycles ou des hétérocycles, leur procédé de préparation, médicaments contenant ces composés et leur utilisation
EP2683699B1 (fr) 2011-03-08 2015-06-24 Sanofi Dérivés oxathiazine di- et tri-substitués, procédé pour leur préparation, utilisation en tant que médicament, agent pharmaceutique contenant ces dérivés et utilisation
WO2012120053A1 (fr) 2011-03-08 2012-09-13 Sanofi Dérivés oxathiazine ramifiés, procédé pour leur préparation, utilisation en tant que médicament, agents pharmaceutiques contenant ces dérivés et leur utilisation
US9321787B2 (en) * 2011-07-07 2016-04-26 Sanofi Carboxylic acid derivatives having an oxazolo[5,4-d]pyrimidine ring
WO2013037390A1 (fr) 2011-09-12 2013-03-21 Sanofi Dérivés amides d'acide 6-(4-hydroxyphényl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylique en tant qu'inhibiteurs de kinase
EP2760862B1 (fr) 2011-09-27 2015-10-21 Sanofi Dérivés d'amide d'acide 6-(4-hydroxyphényl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylique utilisés comme inhibiteurs de kinase
CA2996681C (fr) * 2015-08-27 2024-04-09 Auckland Uniservices Limited Inhibiteurs des tryptophane-dioxygenases (ido1 et tdo) et leur utilisation en therapie

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030114420A1 (en) * 2000-06-28 2003-06-19 Salvati Mark E. Fused cyclic modulators of nuclear hormone receptor function
CA2436576A1 (fr) * 2001-02-02 2002-08-08 Pfizer Inc. Traitement du diabete sucre
AU2001274426A1 (en) 2001-07-04 2003-01-21 Akodi S.A. Web windowed graphical user interface
JP2003033007A (ja) 2001-07-09 2003-01-31 Sanyo Electric Co Ltd チャージポンプ回路の制御方法
CZ2004714A3 (cs) * 2001-12-14 2004-10-13 Novoánordiskáa@S Sloučeniny a jejich použití ke snížení aktivity lipázy citlivé vůči hormonu
EP1581526B1 (fr) 2002-12-18 2009-03-11 Vertex Pharmaceuticals Incorporated Derives de benzisoxazole utiles en tant qu'inhibiteurs des proteines kinases
WO2004094394A1 (fr) * 2003-04-01 2004-11-04 Eli Lilly And Company Amides de l'acide benzisothiazol-3-one-carboxylique inhibiteurs des phospholipase
US7217727B2 (en) * 2003-04-01 2007-05-15 Eli Lilly And Company Phospholipase inhibitors
JP2007529468A (ja) * 2004-03-16 2007-10-25 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ ベンズイソオキサゾール
TW200633990A (en) * 2004-11-18 2006-10-01 Takeda Pharmaceuticals Co Amide compound

Also Published As

Publication number Publication date
KR20080004501A (ko) 2008-01-09
RU2007142657A (ru) 2009-05-27
BRPI0608495A2 (pt) 2010-01-05
NZ562694A (en) 2010-05-28
AU2006237127A1 (en) 2006-10-26
NO20075938L (no) 2007-11-19
EP1874741A1 (fr) 2008-01-09
US8921404B2 (en) 2014-12-30
MY142441A (en) 2010-11-30
IL186635A0 (en) 2008-01-20
MA29393B1 (fr) 2008-04-01
TW200722421A (en) 2007-06-16
RU2414458C2 (ru) 2011-03-20
AR053228A1 (es) 2007-04-25
US20080090867A1 (en) 2008-04-17
CN101160293A (zh) 2008-04-09
WO2006111321A1 (fr) 2006-10-26
MX2007012732A (es) 2008-03-14
CA2606301A1 (fr) 2006-10-26
DE102005018389A1 (de) 2006-10-26
JP2008536884A (ja) 2008-09-11

Similar Documents

Publication Publication Date Title
ZA200707929B (en) Azole derivatives in the form of lipase and phospholipase inhibitors
IL190672A0 (en) Diacyl indazol derivatives as lipase and phospholipase inhibitors
IL250678A0 (en) Compounds and methods for repressing pcsk9 gene expression
ZA200802369B (en) Triazolopyridine derivatives as inhibitors of lipases and phospholipases
IL190714A0 (en) Carbamoylbenzotriazole derivatives as inhibitors of lipases and phospholipases
EP2497470B8 (fr) Imidazotriazines et imidazopyrimidines utilisées en tant qu'inhibiteurs de kinase
IL182726A0 (en) 5-heteroaryl thiazoles and their use as p13k inhibitors
ZA200704888B (en) Pyrrolopyrazines and pyrazolopyrazines useful as inhibitors of protein kinases
SG152225A1 (en) Inhibitors of iap
SI1778718T1 (sl) Inhibitorji IAP
EP1742627A4 (fr) Inhibiteurs de pde4b et leurs utulisations
EP1931205A4 (fr) Inhibiteurs de transglutaminase et methode d'utilisation de ceux-ci
IL196860A0 (en) Benzoxazoles and oxazolopyridines being useful as janus kinases inhibitors
IL201255A0 (en) Imidazolidine carboxamide derivatives as lipase and phospholipase inhibitors
IL187730A0 (en) Azolopyridine-2-on derivatives as lipase and phospholipase inhibitors
IL187728A0 (en) Benzooxazole-2-on derivatives as lipase and phospholipase inhibitors
EP1877424A4 (fr) Inhibiteurs de protéines kinases et leurs utilisations
IL187729A0 (en) Benzothiazol-2-on derivatives as lipase and phospholipase inhibitors
IL181819A0 (en) Enzyme inhibitors and uses thereof
IL186120A0 (en) Inhibitors of neurotrypsin and determination thereof
AU2006259113A8 (en) Use of PDE1C and inhibitors thereof
EP2309859A4 (fr) Inhibiteurs d enzyme et utilisation de ceux-ci
HU0402439D0 (en) Adaptation of laser technology in war industry
HK1142628A1 (en) Compositions and methods for inhibiting expression of the pcsk9 gene
PL381202A1 (pl) Pochodne izochinolinowe i sposoby ich stosowania